BioCentury | Mar 2, 2009
Company News

Replidyne, Cardiovascular Systems deal

...device company Cardiovascular Systems completed their previously announced reverse merger (see BioCentury, Nov. 10, 2008). Replidyne Inc....
BioCentury | Nov 10, 2008
Finance

Ebb & Flow

...on the NYSE. A cash device After looking at more than 120 life sciences companies, Replidyne...
...company, Cardiovascular Systems , as its partner in a reverse merger. On a conference call, Replidyne...
...replication inhibition. But these programs will be shut down on the completion of the merger. Replidyne's...
BioCentury | Nov 10, 2008
Company News

Replidyne, Cardiovascular Systems deal

...device company Cardiovascular Systems. Cardiovascular Systems' stockholders will own 83% of the combined company, and Replidyne...
...Replidyne had no compounds left following a restructuring announced in September (see BioCentury, Sept. 1). Replidyne Inc....
BioCentury | Oct 6, 2008
Finance

Restructuring watch

...infectious and respiratory diagnostic business; reducing headcount by six by closing its Boston office 8/27/08 Replidyne...
BioCentury | Sep 1, 2008
Clinical News

REP3123: Development halted

...is still in the process of reviewing its strategic alternatives (see BioCentury, Dec. 17, 2007). Replidyne Inc....
BioCentury | Sep 1, 2008
Company News

Replidyne infectious news

...Replidyne had $60.7 million in cash (see BioCentury, Dec. 17, 2007, & April 28, 2008). Replidyne Inc....
BioCentury | Jul 7, 2008
Finance

2Q approvals

...PrimoVax trial after GV1001 did not show survival benefit vs. Gemzar gemcitabine in cancer patients Replidyne...
BioCentury | Jun 30, 2008
Company News

Replidyne, Daiichi Sankyo, Nippon Soda Co. Ltd. deal

...terminated its 2004 license agreement with Daiichi Sankyo’s Asubio Pharma Co. Ltd. subsidiary that gave Replidyne...
...develop and commercialize Asubio’s faropenem medoxomil to treat community-acquired infections (see BioCentury, Aug. 23, 2004). Replidyne...
...York, N.Y.) ended a 2006 deal to jointly develop and commercialize faropenem with Replidyne after Replidyne...
BioCentury | Apr 28, 2008
Finance

Ebb & Flow

...soldier on and is in the process of reverting to a Phase II company, while Replidyne...
...million ($63.2 million). At Friday's close, its market cap was £18.8 million ($37.5 million). Meanwhile, Replidyne...
...CDAD). In December, Replidyne restructured and said it was seeking strategic alternatives. At March 31, Replidyne...
BioCentury | Apr 28, 2008
Clinical News

Faropenem medoxomil: Phase III suspended enrollment

...in community-acquired pneumonia (CAP), recommended by FDA in a not approvable letter in October 2006. Replidyne...
...other 3 trials, and further development will depend on securing a partner for the program. Replidyne Inc....
Items per page:
1 - 10 of 103
BioCentury | Mar 2, 2009
Company News

Replidyne, Cardiovascular Systems deal

...device company Cardiovascular Systems completed their previously announced reverse merger (see BioCentury, Nov. 10, 2008). Replidyne Inc....
BioCentury | Nov 10, 2008
Finance

Ebb & Flow

...on the NYSE. A cash device After looking at more than 120 life sciences companies, Replidyne...
...company, Cardiovascular Systems , as its partner in a reverse merger. On a conference call, Replidyne...
...replication inhibition. But these programs will be shut down on the completion of the merger. Replidyne's...
BioCentury | Nov 10, 2008
Company News

Replidyne, Cardiovascular Systems deal

...device company Cardiovascular Systems. Cardiovascular Systems' stockholders will own 83% of the combined company, and Replidyne...
...Replidyne had no compounds left following a restructuring announced in September (see BioCentury, Sept. 1). Replidyne Inc....
BioCentury | Oct 6, 2008
Finance

Restructuring watch

...infectious and respiratory diagnostic business; reducing headcount by six by closing its Boston office 8/27/08 Replidyne...
BioCentury | Sep 1, 2008
Clinical News

REP3123: Development halted

...is still in the process of reviewing its strategic alternatives (see BioCentury, Dec. 17, 2007). Replidyne Inc....
BioCentury | Sep 1, 2008
Company News

Replidyne infectious news

...Replidyne had $60.7 million in cash (see BioCentury, Dec. 17, 2007, & April 28, 2008). Replidyne Inc....
BioCentury | Jul 7, 2008
Finance

2Q approvals

...PrimoVax trial after GV1001 did not show survival benefit vs. Gemzar gemcitabine in cancer patients Replidyne...
BioCentury | Jun 30, 2008
Company News

Replidyne, Daiichi Sankyo, Nippon Soda Co. Ltd. deal

...terminated its 2004 license agreement with Daiichi Sankyo’s Asubio Pharma Co. Ltd. subsidiary that gave Replidyne...
...develop and commercialize Asubio’s faropenem medoxomil to treat community-acquired infections (see BioCentury, Aug. 23, 2004). Replidyne...
...York, N.Y.) ended a 2006 deal to jointly develop and commercialize faropenem with Replidyne after Replidyne...
BioCentury | Apr 28, 2008
Finance

Ebb & Flow

...soldier on and is in the process of reverting to a Phase II company, while Replidyne...
...million ($63.2 million). At Friday's close, its market cap was £18.8 million ($37.5 million). Meanwhile, Replidyne...
...CDAD). In December, Replidyne restructured and said it was seeking strategic alternatives. At March 31, Replidyne...
BioCentury | Apr 28, 2008
Clinical News

Faropenem medoxomil: Phase III suspended enrollment

...in community-acquired pneumonia (CAP), recommended by FDA in a not approvable letter in October 2006. Replidyne...
...other 3 trials, and further development will depend on securing a partner for the program. Replidyne Inc....
Items per page:
1 - 10 of 103